Biologics boom pushes biopharma equipment market toward $116.4b

Asia-Pacific is emerging as the fastest-growing region.

The global biopharmaceutical processing equipment and consumables market is projected to grow to $116.4b due to rising demand for biologics and biosimilars to meet quality and regulatory standards, according to a DelveInsight report.

The report said single-use bioprocessing technologies are increasingly displacing traditional stainless-steel systems, cutting contamination risk and turnaround time whilst lowering operating costs.

Cell and gene therapy production is adding further demand for flexible, small-batch processing equipment, whilst the continued expansion of contract development and manufacturing organisations is fueling sustained purchases of bioreactors, chromatography systems, and automation infrastructure.

Technological shifts — including automated bioreactors, continuous bioprocessing, and artificial intelligence-enabled manufacturing — are pushing equipment upgrades industry-wide.

Moreover, vaccine manufacturing and pandemic-preparedness investment, along with stringent GMP compliance requirements, are reinforcing steady demand for both upstream and downstream processing equipment across all regions.

North America leads the market, accounting for approximately 38% of global revenue in 2025.

It is driven by dense biopharmaceutical manufacturing capacity, sustained R&D investment, and expanding production of monoclonal antibodies, vaccines, and cell and gene therapies.

Meanwhile, Europe's growth is underpinned by an established manufacturing base and rising adoption of continuous bioprocessing.

Asia-Pacific is emerging as the fastest-growing region, with China, India, South Korea, and Japan scaling domestic biologics production through supportive government policy and expanding CDMO capacity.